UA104484C2 - Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань - Google Patents

Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань

Info

Publication number
UA104484C2
UA104484C2 UAA201202536A UAA201202536A UA104484C2 UA 104484 C2 UA104484 C2 UA 104484C2 UA A201202536 A UAA201202536 A UA A201202536A UA A201202536 A UAA201202536 A UA A201202536A UA 104484 C2 UA104484 C2 UA 104484C2
Authority
UA
Ukraine
Prior art keywords
treatment
viral diseases
composition
antiviral substance
multiple action
Prior art date
Application number
UAA201202536A
Other languages
English (en)
Russian (ru)
Inventor
Зеновій Юрійович Ткачук
Original Assignee
Зеновій Юрійович Ткачук
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зеновій Юрійович Ткачук filed Critical Зеновій Юрійович Ткачук
Publication of UA104484C2 publication Critical patent/UA104484C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Винахід стосується способу приготування антивірусних препаратів, який включає модифікацію високо очищеної дріжджової РНК, а також спосіб лікування та профілактики вірусних захворювань, що передбачає введення пацієнтові композиції, яка містить ефективну кількість рибонуклеїнової кислоти для зменшення вірусного навантаження та покращення симптомів захворювання.
UAA201202536A 2011-03-11 2012-03-02 Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань UA104484C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/046,240 US8420617B2 (en) 2011-03-11 2011-03-11 Multiantivirus compound, composition and method for treatment of virus diseases

Publications (1)

Publication Number Publication Date
UA104484C2 true UA104484C2 (uk) 2014-02-10

Family

ID=45841647

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201202536A UA104484C2 (uk) 2011-03-11 2012-03-02 Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань

Country Status (6)

Country Link
US (2) US8420617B2 (uk)
EP (1) EP2683369B1 (uk)
JP (1) JP2014509589A (uk)
RU (1) RU2597150C2 (uk)
UA (1) UA104484C2 (uk)
WO (1) WO2012125306A1 (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694233C2 (ru) * 2017-10-13 2019-07-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Средство, обладающее ноотропным воздействием на организм
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615654A (en) 1968-05-17 1971-10-26 Cpc International Inc Method of treating microbial cells
US3914450A (en) 1973-04-09 1975-10-21 Anheuser Busch Concentrated extract of yeast and processes of making same
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
AU7319994A (en) 1993-06-30 1995-01-24 Board Of Regents, The University Of Texas System Nucleotide preparation and uses thereof in wound healing
US6291637B1 (en) 1994-10-11 2001-09-18 The Regents Of The University Of California Interference with viral IRES-mediated translation by a small yeast RNA reveals critical RNA-protein interactions
ATE449851T1 (de) * 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
US7153839B2 (en) 2000-03-24 2006-12-26 Biocell Laboratories Method of protecting erythricytes, in particular for improvement of blood cytopenia
US6737271B1 (en) 2000-03-24 2004-05-18 Biocell Laboratories Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
AU2002951692A0 (en) * 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
RU2268067C2 (ru) 2003-06-09 2006-01-20 Государственное предприятие Государственный научный центр "Институт иммунологии Федерального медико-биологического агентства" (ГНЦ "Институт иммунологии ФМБА России") Вирусные вакцины
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
US20090203893A1 (en) 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
CN101395168B (zh) 2006-03-01 2011-11-16 日本新药株式会社 半乳糖衍生物、药物载体及医药组合物
WO2008106979A2 (en) 2007-03-02 2008-09-12 Immupharm A/S Pharmaceutical compositions comprising flavonoids and xylitol
CN101980712B (zh) 2007-10-29 2015-02-18 雷古拉斯治疗公司 用于肝癌治疗的靶向微小rna
US7998677B2 (en) 2008-02-26 2011-08-16 Regulus Therapeutics, Inc. MicroRNA detection
RU2398596C2 (ru) * 2008-09-24 2010-09-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Способы профилактики и лечения заболеваний, вызванных вирусом гриппа птиц a/h5n1, с использованием индуктора интерферона и ингибитора нейраминидазы
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof

Also Published As

Publication number Publication date
RU2013143341A (ru) 2015-04-20
US20120232129A1 (en) 2012-09-13
RU2597150C2 (ru) 2016-09-10
EP2683369B1 (en) 2019-09-25
WO2012125306A1 (en) 2012-09-20
US20130217758A1 (en) 2013-08-22
JP2014509589A (ja) 2014-04-21
EP2683369A1 (en) 2014-01-15
US8420617B2 (en) 2013-04-16
US8722642B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
MD4496B1 (ro) Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MX2020011807A (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
IN2014CN00562A (uk)
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
MX2013006342A (es) Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112015010396A2 (pt) terapia de combinação
MY168763A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
IN2014DN06920A (uk)
WO2013058484A3 (ko) 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
NZ629004A (en) Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
WO2011031890A3 (en) Cancer stem cell-targeted and drug resistant cancer therapy
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
NZ606236A (en) Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
MX2015006779A (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.